219 related articles for article (PubMed ID: 21281786)
1. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Vainio P; Gupta S; Ketola K; Mirtti T; Mpindi JP; Kohonen P; Fey V; Perälä M; Smit F; Verhaegh G; Schalken J; Alanen KA; Kallioniemi O; Iljin K
Am J Pathol; 2011 Feb; 178(2):525-36. PubMed ID: 21281786
[TBL] [Abstract][Full Text] [Related]
2. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.
Vainio P; Lehtinen L; Mirtti T; Hilvo M; Seppänen-Laakso T; Virtanen J; Sankila A; Nordling S; Lundin J; Rannikko A; Orešič M; Kallioniemi O; Iljin K
Oncotarget; 2011 Dec; 2(12):1176-90. PubMed ID: 22202492
[TBL] [Abstract][Full Text] [Related]
3. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
4. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.
Massoner P; Kugler KG; Unterberger K; Kuner R; Mueller LA; Fälth M; Schäfer G; Seifarth C; Ecker S; Verdorfer I; Graber A; Sültmann H; Klocker H
PLoS One; 2013; 8(2):e55207. PubMed ID: 23390522
[TBL] [Abstract][Full Text] [Related]
5. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells.
Lehtinen L; Vainio P; Wikman H; Reemts J; Hilvo M; Issa R; Pollari S; Brandt B; Oresic M; Pantel K; Kallioniemi O; Iljin K
J Pathol; 2012 Mar; 226(4):674-86. PubMed ID: 22072156
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
7. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
8. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
[TBL] [Abstract][Full Text] [Related]
9. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
[TBL] [Abstract][Full Text] [Related]
10. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients.
Swami S; Krishnan AV; Moreno J; Bhattacharyya RS; Gardner C; Brooks JD; Peehl DM; Feldman D
Int J Cancer; 2009 May; 124(9):2050-9. PubMed ID: 19127598
[TBL] [Abstract][Full Text] [Related]
12. Monensin is a potent inducer of oxidative stress and inhibitor of androgen signaling leading to apoptosis in prostate cancer cells.
Ketola K; Vainio P; Fey V; Kallioniemi O; Iljin K
Mol Cancer Ther; 2010 Dec; 9(12):3175-85. PubMed ID: 21159605
[TBL] [Abstract][Full Text] [Related]
13. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
14. ERG oncogene modulates prostaglandin signaling in prostate cancer cells.
Mohamed AA; Tan SH; Sun C; Shaheduzzaman S; Hu Y; Petrovics G; Chen Y; Sesterhenn IA; Li H; Sreenath T; McLeod DG; Dobi A; Srivastava S
Cancer Biol Ther; 2011 Feb; 11(4):410-7. PubMed ID: 21178489
[TBL] [Abstract][Full Text] [Related]
15. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
16. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
17. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
18. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Nwachukwu JC; Mita P; Ruoff R; Ha S; Wang Q; Huang SJ; Taneja SS; Brown M; Gerald WL; Garabedian MJ; Logan SK
Cancer Res; 2009 Apr; 69(7):3140-7. PubMed ID: 19318562
[TBL] [Abstract][Full Text] [Related]
20. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells.
Lu S; Wang A; Lu S; Dong Z
Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
